Pyrrhus
Senior Member
- Messages
- 4,172
- Location
- U.S., Earth
Updated ME/CFS prevalence estimates reflecting post-COVID increases and associated economic costs and funding implications (Mirin et al., 2022)
https://doi.org/10.1080/21641846.2022.2062169
From the amazing Art Mirin, Mary Dimmock, and Lenny Jason:
https://doi.org/10.1080/21641846.2022.2062169
From the amazing Art Mirin, Mary Dimmock, and Lenny Jason:
(spacing and emphasis added)Mirin et al. said:In this article, we update our earlier analyses of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) economic impact and its National Institutes of Health (NIH) funding versus disease burden, taking into account the anticipated new cases of ME/CFS resulting from COVID-19.
Prior to the COVID pandemic, we estimated a United States ME/CFS prevalence of 1.5 million and an annual economic impact of $36–51 billion. Now, due to COVID and its resulting post-acute sequalae, we estimate total ME/CFS prevalence could rise to between five and nine million.
This would incur an annual U.S. economic impact of $149 to $362 billion in medical expenses and lost income, exclusive of other costs, such as disability benefits, social services, and lost wages of caretakers.
NIH funding for ME/CFS research would need to expand from the current amount of $15 million per year to approximately $472–$600 million annually, up to a 40-fold increase, to be commensurate with that of similarly burdensome diseases.